Catherine Bollard

🇺🇸United States

Country: 🇺🇸United States

Ownership: -

Employees: -

Market Cap: -

Website

Clinical Trials

HIV Antigen-specific T-cells Targeting Conserved Epitopes (HST-NEETs) BMTCTN1903

Phase 2

Recruiting

Conditions: HIV Associated Lymphoma

Interventions: Biological: HST-NEETs
Biological: Bone Marrow Transplant

First Posted Date: 2021-07-23

Last Posted Date: 2023-12-28

Lead Sponsor: Catherine Bollard

Target Recruit Count: 12

Registration Number: NCT04975698

Locations: 🇺🇸
City of Hope National Medical Center, Duarte, California, United States
🇺🇸
Georgetown, Washington, District of Columbia, United States
🇺🇸
H. Lee Moffitt Cancer Center, Tampa, Florida, United States

and more 8 locations

Evaluate the Safety, Immunologic, and Virologic Responses of Donor Derived (DD) HIV-Specific T-cells (HST) in HIV-infected Individuals Following Allogeneic Bone Marrow Transplantation (alloRESIST)

Phase 1

Recruiting

Conditions: HIV-Infected Individuals

Interventions: Biological: DD HST-NEETs

First Posted Date: 2020-01-30

Last Posted Date: 2023-09-21

Lead Sponsor: Catherine Bollard

Target Recruit Count: 8

Registration Number: NCT04248192

Locations: 🇺🇸
Johns Hopkins University(Jhu), Baltimore, Maryland, United States

Mesenchymal Stromal Cells for Infants With Congenital Heart Disease (MedCaP)

Phase 1

Active, not recruiting

Conditions: Congenital Heart Disease (CHD)

Interventions: Biological: BM-MSC

First Posted Date: 2020-01-22

Last Posted Date: 2023-09-21

Lead Sponsor: Catherine Bollard

Target Recruit Count: 17

Registration Number: NCT04236479

Locations: 🇺🇸
Children's National Health System, Washington, District of Columbia, United States

Tumor Associated Antigen Specific T Cells (TAA-T) With PD1 Inhibitor for Lymphoma

Phase 1

Active, not recruiting

Conditions: Hodgkin Lymphoma
Diffuse Large B Cell Lymphoma

Interventions: Biological: TAA-T cells
Drug: Nivolumab

First Posted Date: 2019-02-18

Last Posted Date: 2024-12-19

Lead Sponsor: Catherine Bollard

Target Recruit Count: 18

Registration Number: NCT03843294

Locations: 🇺🇸
Utah University School of Medicine/Huntsman Cancer Institute, Salt Lake City, Utah, United States

Multi-antigen T Cell Infusion Against Neuro-oncologic Disease

Phase 1

Recruiting

Conditions: Brain Tumor

Interventions: Biological: TAA-T

First Posted Date: 2018-08-29

Last Posted Date: 2024-12-19

Lead Sponsor: Catherine Bollard

Target Recruit Count: 32

Registration Number: NCT03652545

Locations: 🇺🇸
Brain Tumor Institute, Children's National Medical Center, Washington, District of Columbia, United States

Adoptive Cord Blood Immunotherapy for EBV, CMV, BKV and Adenovirus Reactivation/Infection or Prophylaxis

Phase 1

Recruiting

Conditions: Viral Infection

Interventions: Biological: CMV/AdV /EBV/BKV specific T cells

First Posted Date: 2018-07-23

Last Posted Date: 2024-08-28

Lead Sponsor: Catherine Bollard

Target Recruit Count: 36

Registration Number: NCT03594981

Locations: 🇺🇸
Children's National Health System, Washington, District of Columbia, United States
🇺🇸
M.D. Anderson Cancer Center (MDACC), Houston, Texas, United States

HIV-1 Specific T -Cells (HST-NEETs) for HIV-Infected Individuals

Phase 1

Active, not recruiting

Conditions: HIV Infections

Interventions: Biological: HST-NEETs

First Posted Date: 2018-04-03

Last Posted Date: 2024-08-28

Lead Sponsor: Catherine Bollard

Target Recruit Count: 7

Registration Number: NCT03485963

Locations: 🇺🇸
Whitman Walker Health Research Department (Wwh), Washington, District of Columbia, United States
🇺🇸
Children's National Medical Center and WHITMAN WALKER HEALTH RESEARCH DEPARTMENT (WWH), Washington, District of Columbia, United States
🇺🇸
Children's National Hospital, Washington, District of Columbia, United States

Multivirus-specific Cytotoxic T Lymphocytes (mCTL)

Phase 1

Completed

Conditions: Refractory Viral Infections

Interventions: Biological: mCTLs

First Posted Date: 2015-07-29

Last Posted Date: 2020-01-18

Lead Sponsor: Catherine Bollard

Target Recruit Count: 1

Registration Number: NCT02510404

Locations: 🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States

Allogeneic Virus-specific T Cell Lines (VSTs)

Phase 1

Active, not recruiting

Conditions: Viral Infections After HSCT

Interventions: Biological: VSTs

First Posted Date: 2015-07-29

Last Posted Date: 2024-12-19

Lead Sponsor: Catherine Bollard

Target Recruit Count: 31

Registration Number: NCT02510417

Locations: 🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States

Multi-institutional Prospective Research of Expanded Multi-antigen Specifically Oriented Lymphocytes for the Treatment of VEry High Risk Hematopoietic Malignancies

Phase 1

Recruiting

Conditions: Relapsed/Refractory Hematopoietic Malignancies, Acute Myeloid Leukemia and MDS

Interventions: Biological: Tumor associated antigen lymphocytes (TAA-T)

First Posted Date: 2014-07-30

Last Posted Date: 2024-12-19

Lead Sponsor: Catherine Bollard

Target Recruit Count: 90

Registration Number: NCT02203903

Locations: 🇺🇸
Childrens National Medical Center, Washington, District of Columbia, United States
🇺🇸
Kenneth R. Cooke, MD, Baltimore, Maryland, United States

© Copyright 2025. All Rights Reserved by MedPath

Home Terms & Conditions Privacy Policy